课题基金 / 基金详情

Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment

Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment
Fibrillin-1 和 TGFB2 异常模型 POAG 发病机制和治疗
批准号:
9565409
负责人:
CHEE HIAN TAN
金额:
$38.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-30 至 2020-05-31

项目摘要

项目成果

CHEE HIAN TAN的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Primary open angle glaucoma (POAG) is a leading cause of irreversible blindness worldwide. This project's long-term goal is to develop more effective clinical therapy through the discovery and improved understanding of glaucoma pathogenesis. We want to learn how to modify underlying disease mechanisms to an extent that it significantly alters the natural course of disease, preserves vision, and positively impacts patients' lives. This is particularly important in dealing with a chronic, unrelenting disease such as POAG. POAG is of unknown cause, although clinical features and risk factors are known: intraocular pressure (IOP), increasing age, corneal thickness and retinal ganglion cell loss. Levels of transforming growth factor-2 (TGFβ2) in the aqueous humor are elevated and can be considered an important disease biomarker. This can affect the trabecular meshwork's function of regulating physiological aqueous outflow and IOP by inducing fibrogenic change and excessive contractility. Resulting rising IOP damages the retinal ganglion cells, optic nerve and vision. Current IOP-lowering glaucoma therapy targets physiological mechanisms of IOP regulation rather than underlying pathological mechanisms responsible for causing IOP to rise in the first place. We cannot therapeutically target these pathological mechanisms mainly because we do not know what the primary problem is. We have discovered that a mouse with a fibrillin-1 genetic mutation uncannily mimics salient clinical and biochemical features of human POAG. The genetic defect of the mouse immediately invokes pathogenic mechanisms related to fibrillin-1. It offers a unique opportunity to better understand and treat this mysterious and important disease. We propose the following specific aims to: (1) characterize the source of elevated aqueous TGFβ2; (2) assess routes of TGFβ2 activation in the eye tissues and aqueous humor; and (3) test a strategy to prevent harmful effects of aqueous TGFβ2 on the trabecular meshwork and IOP that damages retinal ganglion cells. The mouse model will allow us to better understand the basis for aqueous TGFβ2 elevation in POAG and test a treatment strategy to ameliorate development and progression of the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment
  • 批准号:
    10047754
  • 项目类别:
  • 资助金额:
    $17.93万
  • 财政年份:
    2019
  • 负责人:
    CHEE HIAN TAN
  • 依托单位:
Contractile Modulation of Distal Aqueous Humor Drainage
  • 批准号:
    10047725
  • 项目类别:
  • 资助金额:
    $9.99万
  • 财政年份:
    2019
  • 负责人:
    CHEE HIAN TAN
  • 依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
Role of trabecular meshwork contractility in modulating outflow resistance
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: